BMS-986507 Combinations for Lung Cancer

Recruiting at 52 trial locations

Overseen By BMS Study Connect www.BMSStudyConnect.com

Age: 18+

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: Bristol-Myers Squibb

Disqualifiers: CNS metastases, Heart disease, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 8-12 weeks

218 Participants Needed

Trial Summary

What is the purpose of this trial?

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Do I need to stop taking my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research Team

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Eligibility Criteria

This trial is for adults with advanced solid tumors, which can include various types of cancer that have spread beyond their original location. Specific eligibility details are not provided, but typically participants must meet certain health standards and may need to have tried other treatments first.

Inclusion Criteria

I am fully active or restricted in physically strenuous activity but can do light work.

Participants must have at least one measurable lesion per response evaluation criteria in solid tumors

Participants must have a life expectancy of at least 3 months at the time of the first dose

Exclusion Criteria

My lung cancer is not a mix of SCLC and NSCLC types.

Other protocol-defined Inclusion/Exclusion criteria apply

I do not have a history of severe heart disease.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive BMS-986507 combinations to evaluate safety, tolerability, drug levels, and preliminary efficacy

8-12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• BMS-986507

Trial Overview The study is testing the safety and effectiveness of combining a new drug called BMS-986507 with Osimertinib and Pembrolizumab in treating advanced cancers. It will look at how well patients tolerate the combination therapy and measure its impact on their tumors.

Participant Groups

Group I: Group B Experimental Treatment 2 Interventions

Group II: Group A Experimental Treatment 2 Interventions

Who Is Running the Clinical Trial?

Bristol-Myers Squibb

Lead Sponsor

Trials

2,731

Recruited

4,127,000+

Headquarters

New York City, USA

Known For

Oncology & Cardiovascular

Top Products

Eliquis, Opdivo, Revlimid, Orencia

Christopher Boerner

Bristol-Myers Squibb

Chief Executive Officer since 2023

PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis

Deepak L. Bhatt

Bristol-Myers Squibb

Chief Medical Officer since 2024

MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania